Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | CA1 | P00915 | 14/20 | 0.70 |
| ▸ | CA2 | P00918 | 14/20 | 0.70 |
| ▸ | CA12 | O43570 | 12/20 | 0.70 |
| ▸ | CA9 | Q16790 | 12/20 | 0.70 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.68 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499329 | 0.85 | KMT2A (1.00) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL358576 | 0.83 | CA1 (0.80) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL671546 | 0.82 | CA2 (1.00) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL29941244 | 0.82 | PTPN7 (0.71) | KMT2ACA1CA2CA12CA9 | |
| Acetylsulfanilamide SCHEMBL359721 | 0.82 | CA1 (1.00) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL9280164 | 0.81 | PTPN7 (1.00) | KMT2ACA1CA2CA12CA9 | |
| Bicarbonate SCHEMBL5658794 | 0.81 | KMT2A (0.65) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL10458764 | 0.81 | TIMP3 (0.54) | KMT2ACA1CA2CA12CA9 | |
| Acetylsulfanilamide SCHEMBL8043497 | 0.80 | CA1 (0.96) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL9130898 | 0.80 | GAA (0.68) | KMT2ACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180339963-A1 | ANTICONVULSANT CARBAMATE DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-11-29 | — | — | US | claimed |
| WO-1997027226-A2 | HIGHLY FUNCTIONALIZED POLYETHYLENE GLYCOL GRAFTED POLYSTYRENE SUPPORTS | ARGONAUT TECHNOLOGIES, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| US-20180339963-A1 | ANTICONVULSANT CARBAMATE DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-11-29 | — | — | US | disclosed |
| CN-101472925-B | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| CN-101479267-B | Purine derivatives as A2A agonists | NOVARTIS AG | 2012-05-02 | — | — | CN | disclosed |
| CN-101479267-A | Purine derivatives as A2A agonists | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0874809-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-04 | — | — | EP | disclosed |
| CN-1036395-C | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1997-11-12 | — | — | CN | disclosed |
| WO-1997027226-A2 | HIGHLY FUNCTIONALIZED POLYETHYLENE GLYCOL GRAFTED POLYSTYRENE SUPPORTS | ARGONAUT TECHNOLOGIES, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997025309-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-17 | — | — | WO | disclosed |
| CN-1076446-A | Bridged piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1993-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339963-A1 | ANTICONVULSANT CARBAMATE DERIVATIVES | CNR2, GRIK5, GRIK4 | KMT2A 318/4885CA1 22/4885CA2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.